NATCO Pharma receives warning letter from USFDA for facility in Kothur, Telangana
The company will respond to the Warning Letter within the stipulated timelines
The company will respond to the Warning Letter within the stipulated timelines
A game changing solution for the pharmaceutical industry
Highly effective preservation solutions ensuring the safety and protection of personal care products
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities
Executes the first project for developing and manufacturing a novel anticancer mAb
Subscribe To Our Newsletter & Stay Updated